A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

NCT05706506 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in adults with type 2 diabetes who are switching from a GLP-1 receptor agonist to see how it affects their blood sugar levels.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 152 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-03 · est. completion 2023-10

Where 32 sites · United States

What this study is testing ClinicalTrials.gov NCT05706506 ↗

Description as written by the study sponsor.

The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05706506 ↗